Print

WHO Note on the potential stock-out of paediatric ddI

The HIV/AIDS Department of WHO has issued a note to National AIDS Programmes, procurement agents, and stakeholders on the potential stock-out of paediatric ddl 25mg and 50mg buffered tablets. In the note, WHO recommends a series of short-term actions to minimize the impact of a potential stock-out of paediatric ddl 25mg and 50mg. In addition, a number of longer-term actions are also recommended with the aim of rationalizing the use of ddl products in children in line with the new WHO normative guidance on the use of ARVs in second-line therapy.

The Note is downloadable from:
http://www.who.int/hiv/who_note_ddi_11.pdf


Grantees

  • partners-EN-1
  • partners-EN-2
  • partners-EN-3